FAPi & PSMA PET/CT Imaging for Cancer Detection
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase I trial studies a new imaging technique called FAPi PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulate in normal and cancer tissues in patients with non-prostate cancer. The research team also want to know whether what they see on PET/CT images represents the tumor tissue being excised from the patient's body. The research team is also interested to investigate another new imaging technique called PSMA PET/CT. Participants will be invited to undergo another PET/CT scan, with the PSMA tracer (68Ga-PSMA-11). This is not required but just an option for volunteer patients. Patients who have not received an 18F-FDG PET/CT within one month of enrollment will also undergo an FDG PET/CT scan. The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic information obtained from the PET scan. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of, in the case of this research, 68Ga-PSMA-11 and 68Ga-FAPi, and 18F-FDG (if applicable). Because some cancers take up 68Ga-PSMA-11 and/or 68Ga-FAPi it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs where it occurs in patient's body. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors. The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers. PSMA stands for Prostate Specific Membrane Antigen. This name is incorrect as PSMA is also found in many other cancers. The function of PSMA is not well understood but imaging studies have shown that PSMA can be detected with PET in many non-prostate cancers. Imaging FAP with PET/CT may in the future provide additional information about various cancers.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss this with the research team or your doctor.
Is 68Ga-THP PSMA PET/CT safe for use in humans?
How does the FAPi & PSMA PET/CT imaging treatment differ from other treatments for cancer detection?
The FAPi & PSMA PET/CT imaging treatment is unique because it combines two imaging agents, targeting both fibroblast activation protein (FAP) and prostate-specific membrane antigen (PSMA), which can help detect prostate cancer even when PSMA expression is low. This dual-targeted approach may provide more comprehensive imaging results compared to traditional methods that focus on a single target.14678
What data supports the effectiveness of this treatment for cancer detection?
Research shows that using Gallium Ga 68 FAPi-46 and Gallium Ga 68 PSMA-11 in PET/CT scans can improve the detection of cancerous tumors and their spread compared to traditional methods. These scans have been particularly effective in identifying more cancerous lesions, including small ones, in various types of cancer.29101112
Who Is on the Research Team?
Jeremie Calais
Principal Investigator
UCLA / Jonsson Comprehensive Cancer Center
Are You a Good Fit for This Trial?
This trial is for patients scheduled for cancer surgery who can consent and comply with study procedures. It's open to those with breast, colon, esophageal, gastric, head and neck, lung, ovarian, pancreatic, renal or uterus cancer. Pregnant/nursing individuals or those whose conditions might affect data quality are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants receive 68Ga-FAPi-46 intravenously and undergo PET/CT scan over 20-50 minutes. On another day, they may receive 18F-FDG and undergo PET/CT according to standard of care procedures. Optional 68Ga-PSMA-11 PET/CT for volunteer patients.
Follow-up
Participants are monitored for safety and effectiveness after imaging procedures
What Are the Treatments Tested in This Trial?
Interventions
- 18F-FDG
- Computed Tomography
- Gallium Ga 68 FAPi-46
- Gallium Ga 68-labeled PSMA-11
- Positron Emission Tomography
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jonsson Comprehensive Cancer Center
Lead Sponsor
Society of Nuclear Medecine and Molecular Imaging
Collaborator